- Home
- ACR vs IKT Comparison
ACR vs IKT Comparison
Compare ACR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- IKT
- Stock Information
- Founded
- ACR 2005
- IKT 2008
- Country
- ACR United States
- IKT United States
- Employees
- ACR N/A
- IKT N/A
- Industry
- ACR Real Estate Investment Trusts
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- ACR Real Estate
- IKT Health Care
- Exchange
- ACR Nasdaq
- IKT Nasdaq
- Market Cap
- ACR 139.0M
- IKT 140.5M
- IPO Year
- ACR N/A
- IKT 2020
- Fundamental
- Price
- ACR $17.78
- IKT $1.85
- Analyst Decision
- ACR Buy
- IKT Buy
- Analyst Count
- ACR 2
- IKT 2
- Target Price
- ACR $17.50
- IKT $8.00
- AVG Volume (30 Days)
- ACR 79.2K
- IKT 526.2K
- Earning Date
- ACR 07-30-2025
- IKT 08-13-2025
- Dividend Yield
- ACR N/A
- IKT N/A
- EPS Growth
- ACR N/A
- IKT N/A
- EPS
- ACR 0.34
- IKT N/A
- Revenue
- ACR $83,545,000.00
- IKT N/A
- Revenue This Year
- ACR $3.57
- IKT N/A
- Revenue Next Year
- ACR N/A
- IKT N/A
- P/E Ratio
- ACR $52.11
- IKT N/A
- Revenue Growth
- ACR 6.92
- IKT N/A
- 52 Week Low
- ACR $13.26
- IKT $1.12
- 52 Week High
- ACR $23.81
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- ACR 47.60
- IKT 47.71
- Support Level
- ACR $17.59
- IKT $1.80
- Resistance Level
- ACR $18.10
- IKT $2.09
- Average True Range (ATR)
- ACR 0.47
- IKT 0.14
- MACD
- ACR 0.05
- IKT 0.03
- Stochastic Oscillator
- ACR 51.44
- IKT 54.72
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.